Removal of Drugs for Alzheimer’s Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA)-Reference-Cited by-同舟云学术

Removal of Drugs for Alzheimer’s Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA)

Published:2021-01 Issue:1 Volume:38 Page:63-74
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

Herr Marie^ORCID,Ankri Joël,Diard Capucine,Hiance-Delahaye Anne

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

http://link.springer.com/content/pdf/10.1007/s40266-020-00817-3.pdf

Reference21 articles.

1. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006. https://doi.org/10.1002/14651858.CD005593.

2. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD003154.pub6.

3. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903. https://doi.org/10.1056/NEJMoa1106668.

4. Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, et al. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer’s disease: a meta-analysis. Swiss Med Wkly. 2019;149:w20093. https://doi.org/10.4414/smw.2019.20093

5. Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126. https://doi.org/10.1186/s13195-018-0457-9.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA‐DEM cohort;British Journal of Clinical Pharmacology;2024-06-26

2. Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK;JAMA Health Forum;2022-08-05

3. Des traitements symptomatiques qui ne sont plus remboursés mais qui sont toujours utilisés dans la maladie d’Alzheimer : pourquoi ?;La Presse Médicale Formation;2022-03

4. Evolution in the dispensation of drugs for Alzheimer's disease after removal from the list of reimbursable drugs in France;Journal of the American Geriatrics Society;2021-04-05